REFERENCES
  1. Hall SF, Walker H, Siemens R, Schneeberg A. Increasing detection and increasing incidence in thyroid cancer. World journal of surgery: official journal of the international society of surgery/société internationale de chirurgie . 2009;33(12):2567-2571. doi:10.1007/s00268-009-0226-9
  2. Sosa J, Hanna J, Robinson K, Lanman, R. (2013). Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the united states. Surgery,  154 (6), 1420-6. doi:10.1016/j.surg.2013.07.006
  3. Lewis C, Chang K, Pitman M, Faquin W, Randolph G. (2009). Thyroid fine-needle aspiration biopsy: Variability in reporting. Thyroid: Official Journal of the American Thyroid Association,19 (7), 717-23. doi:10.1089/thy.2008.0425
  4. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341-1346.
  5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016. Jan;26(1):1-133. doi: 10.1089/thy.2015.0020
  6. Varshney R, Forest V-I, Mascarella MA, Zawawi F, Rochon L, Hier MP, Mlynarek A, Tamilia M, Payne RJ. The mcgill thyroid nodule score – does it help with indeterminate thyroid nodules? Journal of otolaryngology - head & neck surgery . 2015;44(1). doi:10.1186/s40463-015-0058-6
  7. Valderrabano P, Khazai L, Thompson Z, Leon M, Otto K, Hallanger-Johnson J, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. (2017). Cancer risk stratification of indeterminate thyroid nodules: A cytological approach. Thyroid: Official Journal of the American Thyroid Association,27 (10), 1277-1284. doi:10.1089/thy.2017.0221
  8. Mehta V, Nikiforov Y, Ferris RL. (2013). Use of molecular biomarkers in fna specimens to personalize treatment for thyroid surgery. Head & Neck,  35 (10), 1499-506. doi:10.1002/hed.23140
  9. Bhaijee F, Nikiforov YE. Molecular analysis of thyroid tumors. Endocrine pathology . 2011;22(3):126-133. doi:10.1007/s12022-011-9170-y
  10. Krasner JR, Alyouha N, Pusztaszeri M, Forest VI, Hier MP, Avior G, Payne RJ. Molecular mutations as a possible factor for determining extent of thyroid surgery. J Otolaryngol Head Neck Surg . 2019;48(1):1-7. doi:10.1186/s40463-019-0372-5
  11. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. Braf mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. The journal of clinical endocrinology and metabolism . 2003;88(11):5399-5404.
  12. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park DJ. The association of the braf(v600e) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer . 2012;118(7):1764-1773. doi:10.1002/cncr.26500
  13. Elisei R, Viola D, Torregrossa L, Giannini R, ROmei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F. The braf(v600e) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. The journal of clinical endocrinology and metabolism . 2012;97(12):4390-4398. doi:10.1210/jc.2012-1775
  14. Li C, Lee KC, Schneider EB, Zeiger MA. Braf v600e mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. The journal of clinical endocrinology and metabolism . 2012;97(12):4559-4570. doi:10.1210/jc.2012-2104
  15. Xing M, Westra WH, Tufano RP, B Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. Braf mutation predicts a poorer clinical prognosis for papillary thyroid cancer. The journal of clinical endocrinology and metabolism . 2005;90(12):6373-6379.
  16. Celik M, Bulbul BY, Ayturk S, Durmus Y, Gurkan H, Can N, Tastekin E, Ustun F, Sezer A, Guldiken S.The relation between brafv600e mutation and clinicopathological characteristics of papillary thyroid cancer. Medicinski glasnik : official publication of the medical association of zenica-doboj canton, bosnia and herzegovina . 2020;17(1). doi:10.17392/1086-20
  17. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. The american journal of surgical pathology . 2006;30(2):216-222.
  18. Patel SG, Carty SE, McCoy KL, Ohori NP, LeBeau SO, Seethala R, Nikiforova MN, Nikiforov YE, Yip L. Preoperative detection of ras mutation may guide extent of thyroidectomy. Surgery . 2017;161(1):168-175. doi:10.1016/j.surg.2016.04.054
  19. Guan H, Toraldo G, Cerda SR, Godley FA, Rao SR, McAneny D, Doherty G, Braverman L, Lee SL. Utilities of ras mutations in pre-operative fine needle biopsies for decision-making for thyroid nodule management: results from a single-center prospective cohort. Thyroid: official journal of the american thyroid association . 2020;2020 Jan 29. doi:10.1089/thy.2019.0116
  20. Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, Carty SE. The american association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults. Annals of surgery . 2020;271(3):93. doi:10.1097/SLA.0000000000003580
  21. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Steward AF, Nikiforova MN. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 fna samples. The journal of clinical endocrinology and metabolism . 2011;96(11):3390-3397. doi:10.1210/jc.2011-1469
  22. Muzza M, Colombo C, Pogliaghi G, Karapanou O, Fugazzola L. Molecular markers for the classification of cytologically indeterminate thyroid nodules. Journal of endocrinological investigation. 2019;2019 Dec 18. doi:10.1007/s40618-019-01164-w
  23. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, CHudova D, Diggans J, Friedman L, Kloos RT, Livolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. The new england journal of medicine . 2012;367(8):705-715. doi:10.1056/NEJMoa1203208
  24. Roth MY, Witt RL, Steward DL. Molecular testing for thyroid nodules: review and current state. Cancer . 2018;124(5):888-898. doi:10.1002/cncr.30708
  25. Huy Gia Vuong, Uyen N P Duong, Ahmed M A Altibi, Ngo HTT, Pham TQ, Tran HM, Gandolfi G, Hassell L. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocrine connections . 2017;6(3):17. doi:10.1530/EC-17-0010